Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 11 2024 - 5:00PM
Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on
June 10, 2024, the Compensation Committee of its Board of Directors
granted inducement equity grants to three new employees, consisting
of inducement restricted stock units, or RSUs, covering an
aggregate of 10,500 shares of its common stock. These inducement
RSUs are subject to the terms of Travere’s 2018 Equity Incentive
Plan (“2018 Plan”), but were granted outside of the 2018 Plan and
were granted as inducements material to the new employees entering
into employment with Travere in accordance with Nasdaq Listing Rule
5635(c)(4).
The RSUs vest over four years, with 25% of the
shares vesting on each anniversary of the grant date, subject to
the new employee’s continued service relationship with Travere
through the applicable vesting dates.
About Travere Therapeutics
At Travere Therapeutics, we are in rare for
life. We are a biopharmaceutical company that comes together every
day to help patients, families, and caregivers of all backgrounds
as they navigate life with a rare disease. On this path, we know
the need for treatment options is urgent – that is why our global
team works with the rare disease community to identify, develop,
and deliver life-changing therapies. In pursuit of this mission, we
continuously seek to understand the diverse perspectives of rare
patients and to courageously forge new paths to make a difference
in their lives and provide hope – today and tomorrow. For more
information, visit travere.com.
Contact InfoMedia:
888-969-7879
mediarelations@travere.com |
Investors:
888-969-7879
IR@travere.com |
Travere Therapeutics (NASDAQ:TVTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Travere Therapeutics (NASDAQ:TVTX)
Historical Stock Chart
From Jul 2023 to Jul 2024